An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era
Open Access
- 2 January 2018
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 1-8
Abstract
Systemic inflammatory parameters are associated with poor outcomes in malignant patients. Several inflammation-based cumulative prognostic score systems were established for various solid tumors. However, there is few inflammation based cumulative prognostic score system for patients with diffuse large B cell lymphoma (DLBCL). We retrospectively reviewed 564 adult DLBCL patients who had received rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) therapy between Nov 1 2006 and Dec 30 2013 and assessed the prognostic significance of six systemic inflammatory parameters evaluated in previous studies by univariate and multivariate analysis:C-reactive protein(CRP), albumin levels, the lymphocyte-monocyte ratio (LMR), the neutrophil-lymphocyte ratio(NLR), the platelet-lymphocyte ratio(PLR)and fibrinogen levels. Multivariate analysis identified CRP, albumin levels and the LMR are three independent prognostic parameters for overall survival (OS). Based on these three factors, we constructed a novel inflammation-based cumulative prognostic score (ICPS) system. Four risk groups were formed: group ICPS = 0, ICPS = 1, ICPS = 2 and ICPS = 3. Advanced multivariate analysis indicated that the ICPS model is a prognostic score system independent of International Prognostic Index (IPI) for both progression-free survival (PFS) (p < 0.001) and OS (p < 0.001). The 3-year OS for patients with ICPS =0, ICPS =1, ICPS =2 and ICPS =3 were 95.6, 88.2, 76.0 and 62.2%, respectively (p < 0.001). The 3-year PFS for patients with ICPS = 0–1, ICPS = 2 and ICPS = 3 were 84.8, 71.6 and 54.5%, respectively (p < 0.001). The prognostic value of the ICPS model indicated that the degree of systemic inflammatory status was associated with clinical outcomes of patients with DLBCL in rituximab era. The ICPS model was shown to classify risk groups more accurately than any single inflammatory prognostic parameters. These findings may be useful for identifying candidates for further inflammation-related mechanism research or novel anti-inflammation target therapies.Keywords
Funding Information
- the National Natural Science Foundation of China (NSFC) projects (81230045)
- the Ministry of Science and Technology fund of China (2012CB967003)
This publication has 45 references indexed in Scilit:
- Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective reviewBMC Cancer, 2013
- Blood Lymphocyte-to-Monocyte Ratio Identifies High-Risk Patients in Diffuse Large B-Cell Lymphoma Treated with R-CHOPPLOS ONE, 2012
- New Strategies in Diffuse Large B-cell Lymphoma: Translating Findings from Gene Expression Analyses into Clinical PracticeClinical Cancer Research, 2011
- Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With RituximabJournal of Clinical Oncology, 2011
- Gastric MALT lymphoma: a model of chronic inflammation-induced tumor developmentNature Reviews Gastroenterology & Hepatology, 2010
- The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: An overview with emphasis on the myeloid neoplasmsChemico-Biological Interactions, 2010
- Immunity, Inflammation, and CancerCell, 2010
- A cytokine-mediated link between innate immunity, inflammation, and cancerJournal of Clinical Investigation, 2007
- NF-κB: linking inflammation and immunity to cancer development and progressionNature Reviews Immunology, 2005
- Cytokines in cancer pathogenesis and cancer therapyNature Reviews Cancer, 2004